© Reuters.
Thermo Fisher Scientific (NYSE:), a global leader in the science services sector, is predicted to witness a 37.18% upside in its stock, reaching a one-year price target of $633.51, according to an Overweight recommendation by Morgan Stanley. The company, which generates over $25 billion in annual revenue and holds a mission to create a healthier, cleaner, safer world, is anticipated to see an annual revenue growth of 2.39%, hitting $44,563 million.
Despite this optimistic projection, the company has recently experienced a 54.43% drop in institutional shares to 378,104K shares. This decline occurred even as the number of fund owners increased, suggesting a bearish market sentiment with a put/call ratio of 1.02.
Capital World Investors, VTSMX – Vanguard Total Stock Market Index Fund Investor Shares, VFINX – Vanguard 500 Index Fund Investor Shares, Price T Rowe Associates, and Geode Capital Management are among the key stakeholders of Thermo Fisher Scientific. These entities have witnessed varying changes in their holdings.
The company’s non-GAAP EPS is forecasted to be 23.50. This prediction aligns with Thermo Fisher Scientific’s ongoing efforts and commitment towards its mission of leading the global science services sector and contributing to a healthier world.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Read the full article here
